EC Microbiology

Research Article Volume 20 Issue 2 - 2023

Trends and Outlook for Stem Cell Therapy in Lung Damage Patients

Raghavendra Rao MV1*, Aruna Kumari B2, Uday Goutham Nookathota3,  Alluri Neeraja3, Divya Pingili4, Srinivasa Rao Gummadidala6 and M M Karindas5

1Scientist-Emeritus, and Director Research, Apollo Institute of Medical Sciences and Research, Hyderabad, Telangana, India

2Consultant Pulmonologist, Shruthi Super Specialties Hospitals, Vijaynagar Colony, Hyderabad, Telangana, India

3Consultant Neurosurgeon, Goutham Neuro Care 261MIG, KPHB Colony, Road Number 4 Kukatpally, Hyderabad, Telangana, India

4Associate Professor, College of Pharmacy, Madhapur, Hyderabad, Telangana, India

5Professor of Oncology, World Academy of Medical Sciences, Netherlands

6Associate professor, Department of Radiology, Dr.VRK Women's Medical college,Teaching hospital and research centre, Hyderabad, India

*Corresponding Author: Raghavendra Rao MV, Scientist-Emeritus, and Director Research, Apollo Institute of Medical Sciences and Research, Hyderabad, Telangana, India.
Received: October 06, 2023; Published: January 31, 2024




Stem cell therapy is regenerative medicinal therapy used to repair damaged cells by lowering inflammation and controlling the immune system. Stem cells differentiate into cell types requested for repair. Cell therapy is useful for treating chaotic, hysterical pulmonary sickness. 

The stem cell treatment has been found safe and well tolerable.

Currently, most of the stem cell trials are at an early stage for assessing the worth of safety, practicability, tolerance, and productiveness. Stem cell therapy on respiratory diseases needs to be studied by phase III and IV clinical trials. Mesenchymal stromal cell (MSC)-Stem cell based therapies provide a platform for new therapeutic strategies in lung diseases. Cell-based therapies are costly treatments.

The global stem cell therapy market size was estimated at USD 11.22 billion in 2022 and it is projected to reach around USD 31.41 billion by 2030. Approximately 87.5% of our total patient population reported sustained improvement in their condition within three months of treatment.

 Keywords: Pulmonary Diseases; COVID-19; Cell Therapy; Mesenchymal Stem Cells (MSCs); Bronchopulmonary Dysplasia (BPD); Pulmonary Fibrosis

  1. Hogan BL., et al. “Repair and regeneration of the respiratory system: complexity, plasticity, and mechanisms of lung stem cell function”. Cell Stem Cell 15 (2014): 123-138.
  2. Chinazzi M., et al. “The effect of travel restrictions on the spread of the 2019 novel coronavirus (COVID-19) outbreak”. Science 368 (2020): 395-400.
  3. Adeloye D., et al. “Global Health Epidemiology Reference Group (GHERG) Global and regional estimates of COPD prevalence: Systematic review and meta-analysis”. Journal of Global Health 5 (2015): 020415.
  4. Weiss DJ., et al. “ATS Subcommittee on Stem Cells and Cell Therapies. An official American Thoracic Society workshop report: stem cells and cell therapies in lung biology and diseases”. Annals of the American Thoracic Society 12 (2015): S79-S97.
  5. Yeo RW., et al. “Mesenchymal stem cell: an efficient mass producer of exosomes for drug delivery”. Advanced Drug Delivery Reviews 65 (2013): 336-341.
  6. Islam MN., et al. “Mitochondrial transfer from bone-marrow-derived stromal cells to pulmonary alveoli protects against acute lung injury”. Nature Medicine 18 (2012): 759-765.
  7. Yan Q., et al. “A site-specific genetic modification for induction of pluripotency and subsequent isolation of derived lung alveolar epithelial type II cells”. Stem Cells2 (2014): 402-413.
  8. Averyanov A., et al. “First-in-human high-cumulative-dose stem cell therapy in idiopathic pulmonary fibrosis with rapid lung function decline”. Stem Cells Translational Medicine 9 (2019): 6-16.
  9. Herberts CA., et al. “Risk factors in the development of stem cell therapy”. Journal of Translational Medicine 9 (2011): 29.
  10. Castillo Aleman YM., et al. “Viability assessment of human peripheral blood-derived stem cells after three methods of nebulization”. American Journal of Stem Cells4 (2021): 68-78.
  11. Kabat M., et al. “Trends in mesenchymal stem cell clinical trials 2004-2018: Is efficacy optimal in a narrow dose range?” Stem Cells Translational Medicine1 (2020): 17-27.
  12. Galipeau J and Sensebe L. “Mesenchymal stromal cells: clinical challenges and therapeutic opportunities”. Cell Stem Cell6 (2018): 824-833.
  13. Liu M., et al. “Stem cell and idiopathic pulmonary fibrosis: mechanisms and treatment”. Current Stem Cell Research and Therapy 10 (2015): 466-476.
  14. Fu X., et al. “Mesenchymal stem cell migration and tissue repair”. Cells 8 (2019): 784.
  15. T Xu., et al. “Mesenchymal stem cell-based therapy for radiation-induced lung injury”. Stem Cell Research and Therapy1 (2018): 18.
  16. M Gazdic., et al. “Mesenchymal stem cells: a friend or foe in immune-mediated diseases”. Stem Cell Reviews 11.2 (2015): 280-287.
  17. P Macchiarini., et al. “Clinical transplantation of a tissue-engineered airway”. Lancet 372 (2008): 2023-2030.
  18. HJ Rippon., et al. “Embryonic stem cells as a source of pulmonary epithelium in vitro and in vivo”. Proceedings of the American Thoracic Society 5 (2008): 717-722.
  19. Kennelly H., et al. “Human mesenchymal stromal cells exert HGF dependent cytoprotective effects in a human relevant pre-clinical model of COPD”. Scientific Reports 6 (2016): 38207.
  20. Yun-Tian Chen., et al. “Stem cell therapy for chronic obstructive pulmonary disease”. Chinese Medical Journal13 (2021): 1535-1545.
  21. Le Thi Bich P., et al. “Allogeneic umbilical cord-derived mesenchymal stem cell transplantation for treating chronic obstructive pulmonary disease: a pilot clinical study”. Stem Cell Research Therapy (2020).
  22. Wenzhao Cheng., et al. “Stem cell-based therapy for pulmonary fibrosis”. Stem Cell Research and Therapy 13 (2022): 492.
  23. Willis GR., et al. “Mesenchymal stromal cell exosomes ameliorate experimental bronchopulmonary dysplasia and restore lung function through macrophage immunomodulation”. American Journal of Respiratory and Critical Care Medicine1 (2018): 104-116.
  24. Mansouri N., et al. “Mesenchymal stromal cell exosomes prevent and revert experimental pulmonary fibrosis through modulation of monocyte phenotypes”. JCI Insight 4 (2019): e128060.
  25. Coraux C., et al. “Embryonic stem cells generate airway epithelial tissue”. American Journal of Respiratory Cell and Molecular Biology2 (2005): 87-92.
  26. ATS Public Health Information Series © American Thoracic Society American Journal of Respiratory and Critical Care Medicine 195 (2017): P13-P14.
  27. Hong-Long Ji., et al. “Stem cell therapy for COVID-19 and other respiratory diseases: Global trends of clinical trials”. World Journal of Stem Cells6 (2020): 471-480.
  28. Yadav H., et al. “Fifty years of research in ARDS. Is acute respiratory distress syndrome a preventable disease?” American Journal of Respiratory and Critical Care Medicine 6 (2017): 725-736.
  29. Matthay MA., et al. “Concise review: Mesenchymal stem (stromal) cells: biology and preclinical evidence for therapeutic potential for organ dysfunction following trauma or sepsis”. Stem Cells2 (2017): 316-324.
  30. Walter J., et al. “Mesenchymal stem cells: mechanisms of potential therapeutic benefit in ARDS and sepsis”. The Lancet Respiratory Medicine12 (2014): 1016-1026.
  31. Zheng G., et al. “Treatment of acute respiratory distress syndrome with allogeneic adipose-derived mesenchymal stem cells: a randomized, placebo-controlled pilot study”. Respiratory Research 15 (2014): 39.
  32. Wilson JG., et al. “Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial”. The Lancet Respiratory Medicine1 (2015): 24-32.
  33. Augustine S., et al. “Are all stem cells equal? Systematic review, evidence map, and meta-analyses of preclinical stem cell-based therapies for bronchopulmonary dysplasia: Concise review”. Stem Cells Translational Medicine (2019).
  34. Nitkin CR., et al. “Stem cell therapy for preventing neonatal diseases in the 21st century: Current understanding and challenges”. Pediatric Research2 (2019): 256-276.
  35. Chang YS., et al. “Mesenchymal stem cells for bronchopulmonary dysplasia: phase 1 dose-escalation clinical trial”. The Journal of Pediatrics5 (2014): 966-972.
  36. Ahn SY., et al. “Two-year follow-up outcomes of premature infants enrolled in the phase I trial of mesenchymal stem cells transplantation for bronchopulmonary dysplasia”. The Journal of Pediatrics 185 (2017): 49-54.

Raghavendra Rao MV., et al. “Trends and Outlook for Stem Cell Therapy in Lung Damage Patients”. EC Microbiology  20.2 (2024): 01-08.

ECronicon Journal

Our Services

Quick Links

Information

Creative Commons LicenseOpen Access by ECronicon is licensed under a Creative Commons Attribution 4.0 International License
Based on a work at www.ecronicon.net